Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.

Nicholson, Martha K, Ghazal Asswad, Randa and Wilding, John Ph ORCID: 0000-0003-2839-8404
(2021) Dapagliflozin for the treatment of type 2 diabetes mellitus - an update. Expert opinion on pharmacotherapy. 1 - 8.

Access the full-text of this item by clicking on the Open Access link.


<h4>Introduction</h4>Diabetes is a global health concern with a prevalence of 463 million people. Importantly, despite the availability of numerous antidiabetic medications, type 2 diabetes mellitus (T2DM) is still associated with significant morbidity and mortality worldwide. One particular drug of interest is dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is commonly used in the treatment of Type 2 Diabetes Mellitus (T2DM).<h4>Areas covered</h4>This review outlines the current use and pharmacology of dapagliflozin, with a specific focus on recent evidence regarding benefits in patients with cardiovascular and chronic kidney disease. The article includes an overview of the efficacy and safety of this drug and provides the reader with the expert opinion and perspectives of the authors.<h4>Expert opinion</h4>Increasing evidence of the beneficial effects on morbidity and mortality in patients with Type 2 diabetes and concurrent heart failure, acute MI and renal failure are likely to see the usage of dapagliflozin in patients with these comorbidities increase over the next 5 years.

Item Type: Article
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User: Symplectic Admin
Date Deposited: 02 Aug 2021 08:08
Last Modified: 09 Aug 2022 18:10
DOI: 10.1080/14656566.2021.1953471
Open Access URL: https://www.tandfonline.com/doi/full/10.1080/14656...
URI: https://livrepository.liverpool.ac.uk/id/eprint/3131816